Publications by authors named "Brigitte A H A Bogaarts"
Article Synopsis
- Prednisone is the first-line treatment for pulmonary sarcoidosis but comes with several side effects, while methotrexate is the second-line option with fewer side effects but slower action.
- A noninferiority trial involving 138 patients compared the effects of prednisone and methotrexate on lung function at 24 weeks, finding that methotrexate's efficacy was comparable to that of prednisone.
- Both treatment groups experienced similar adverse events, with prednisone leading to weight gain and insomnia, while methotrexate was associated with nausea and fatigue.
Lung Function Course of Patients With Pulmonary Fibrosis After Initiation of Anti-Fibrotic Treatment: Real-World Data From the Dutch National Registry.
Respirology
May 2025
Background And Objective: Real-world data on lung function course of patients with progressive pulmonary fibrosis (PPF) treated with anti-fibrotic medication are limited. We evaluated forced vital capacity (FVC) decline in patients with PPF and idiopathic pulmonary fibrosis (IPF) who started anti-fibrotic treatment.
Methods: This was a nationwide multi-centre registry study in 16 hospitals throughout the Netherlands.
Chemotherapy and Tyrosine Kinase Inhibitors in the last month of life in patients with metastatic lung cancer: A patient file study in the Netherlands.
Eur J Cancer Care (Engl)
March 2020
Objective: Chemotherapy in the last month of life for patients with metastatic lung cancer is often considered as aggressive end-of-life care. Targeted therapy with Tyrosine Kinase Inhibitors (TKIs) is a relatively new treatment of which not much is known yet about use in the last month of life. We examined what percentage of patients received chemotherapy or TKIs in the last month of life in the Netherlands.
View Article and Find Full Text PDFIs In-Hospital Mortality Higher in Patients With Metastatic Lung Cancer Who Received Treatment in the Last Month of Life? A Retrospective Cohort Study.
J Pain Symptom Manage
November 2019
Context: Metastatic lung cancer is an incurable disease that results in a high burden of symptoms, a poor quality of life, and an expected prognosis of less than one year after diagnosis. Treatment shortly before death may result in potential burdensome and inappropriate hospital admissions and hospital deaths. Dying at home is, at a population level, considered a quality for good end-of-life care.
View Article and Find Full Text PDFStage III Non-Small Cell Lung Cancer in the elderly: Patient characteristics predictive for tolerance and survival of chemoradiation in daily clinical practice.
Radiother Oncol
October 2016
Background: In unselected elderly with stage III Non-Small Cell Lung Cancer (NSCLC), evidence is scarce regarding motives and effects of treatment modalities.
Methods: Hospital-based multicenter retrospective study including unresectable stage III NSCLC patients aged ⩾70 and diagnosed between 2009 and 2013 (N=216). Treatment motives and tolerance (no unplanned hospitalizations and completion of treatment), and survival were derived from medical records and the Netherlands Cancer Registry.